Tempest Therapeutics, Inc.
Amezalpat
hepatocellular carcinoma
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Amezalpat in hepatocellular carcinoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“planned for 2027”